Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on Telomir-1 as a potential treatment for age-related conditions, has summarized its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, DC, on April 15, 2024.

Dr. Chris Chapman, Co-founder, Chairman, CEO, President and Chief Medical Officer of Telomir, and Dr. Michael Roizen, special advisor to Telomir on age reversal, spearheaded the presentation, showcasing the remarkable prospects for Telomir- 1 to potentially allow the body to repair itself and mitigate effects typically associated with aging.

As part of its commitment to transparency and openness in sharing its research data, during the event, Drs. Chapman and Roizen presented company data that showed the effect of Telomir-1, a novel molecule designed to modulate telomerase activity and elongate telomeres. The data show that telomeres lengthened in vitro in human cells and telomerase activity increased by 40 percent. 

The presentation also described demonstrable pre-clinical animal testing endpoints for determining Telomir-1’s potential for ‘age reversal’ or ‘anti-aging’ effects such as gait strength or weakness, joint damage assessment, dynamic weight bearing, clinical chemistry, hematology, telomere length and change in synovial fluids.

Dr. Chapman also outlined the anticipated timeline for initiating human clinical trials for osteoarthritis, along with veterinary clinical trials, both of which are targeted for the second and third quarter of 2025 following anticipated pre-clinical, IND-enabling studies in animals during 2024.

“Our National Press Club event was our first opportunity to share on a national stage Telomir-1’s potential to combat the diseases of aging,” stated Dr. Chapman.

“We believe that the pre-clinical data were encouraging and demonstrated Telomir-1’s potential to treat age-related conditions. We remain committed to keeping the public updated as we move through the pre-clinical, IND and AIND processes and beyond,” commented Dr. Chapman.

Dr. Roizen, Chief Wellness Officer Emeritus at Cleveland Clinic, emphasized Telomir-1's innovative approach to combating aging-related conditions, including diseases such as osteoarthritis, and highlighted the scientific principles underlying stem cell regulation.

Acknowledging the invaluable contributions of Telomir-1's expert panel (the GeorgeTown Group) on longevity which was formed in December 2023, Dr. Roizen expressed gratitude for their collaboration and dedication. The distinguished panel, comprising 14 individuals from the fields of medicine, medical ethics, public relations, law and economics, further demonstrates a multi-pronged approach in shaping Telomir-1's research direction.

“Sharing our pre-clinical results with the public was a significant step for Telomir, particularly with the strong interest in this important work that the longevity community has expressed,” said Dr. Roizen.

“We are grateful for the support of our expert panel without whom this event would not have been possible. It allowed us to present our findings to the attendees and to share with them the progress Telomir is making toward developing and commercializing Telomir-1 to reverse age-related conditions,” added Dr. Roizen.